Iota-Carrageenan

DRUG3 trials

Sponsors

Boehringer Ingelheim, NicOx, Ariel Dogliotti

Conditions

Adenoviral ConjunctivitisCommon ColdCovid19

Phase 2

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

WithdrawnNCT03009799

NicOxAdenoviral Conjunctivitis

Start: 2017-01-31End: 2017-09-30Updated: 2017-05-10

Phase 4

Iota-Carrageenan Nasal Spray in Common Cold

CompletedNCT01944631

Boehringer IngelheimCommon Cold

Start: 2013-09-30End: 2014-03-31Updated: 2015-04-03

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease

Ariel DogliottiCovid19

Start: 2020-07-24End: 2020-11-30Target: 400Updated: 2020-08-21

Related Papers

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease

International Journal of General Medicine2021-09-3073 citations

Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.

2015-10-0561 citations